Apr. 1 at 11:41 PM
$BMEA Part 4/5
Back at the payers meeting, Ramses says: “Guys, relax. Here’s the deal: doctors add icovamenib to the existing therapy which is failing. 26 weeks later, they check HbA1c. If it’s down by 0.5% or more, all is good and they gradually reduce the current therapy dose. You’re happy, the patient’s happy, the doctor’s happy and Biomea is happy. If, on the other hand, icovamenib isn’t able to make a real, long term difference of at least 0.5%, Biomea reimburses the payer for its cost. In other words, you only pay if it works.”
The frowns turn into smiles because the math is a pure win‑win: if it fails, it costs nothing; if it works, payers save tens of billions per year by de‑escalating GLP‑1s, avoiding insulin, and avoiding complications. Suddenly, icovamenib becomes a no‑risk lever that can reshape the entire T2D food chain. And yes — this model already exists and is growing in popularity in the pharma/payer business. It’s called “value‑based contracts”.
